Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics' Other Non-Current Liabilities history spans 6 years, with the latest figure at $43.9 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 11.34% year-over-year to $43.9 million; the TTM value through Sep 2025 reached $43.9 million, down 11.34%, while the annual FY2024 figure was $37.7 million, 1748.58% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $43.9 million at Insight Molecular Diagnostics, up from $40.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $52.0 million in Q3 2022 and bottomed at $2.0 million in Q1 2024.
  • The 5-year median for Other Non-Current Liabilities is $26.3 million (2023), against an average of $25.1 million.
  • The largest annual shift saw Other Non-Current Liabilities crashed 95.6% in 2023 before it skyrocketed 2064.41% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $7.1 million in 2021, then surged by 503.48% to $42.6 million in 2022, then plummeted by 95.21% to $2.0 million in 2023, then skyrocketed by 1748.58% to $37.7 million in 2024, then increased by 16.53% to $43.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other Non-Current Liabilities are $43.9 million (Q3 2025), $40.9 million (Q2 2025), and $38.4 million (Q1 2025).